Logo
x

Search

Subscribe Now

HER2-positive

Tanvex Reports Results of TX05 (biosimilar- trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer

Tanvex Reports Results of TX05 (biosimilar- trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer

  • February 20, 2021
Chugai's Kadcyla (trastuzumab emtansine) Receives MHLW's Approval for Adjuvant Therapy of HER2-Positive Early Breast Cancer

Chugai's Kadcyla (trastuzumab emtansine) Receives MHLW's Approval for Adjuvant Therapy of HER2-Positive Early Breast Cancer

  • August 24, 2020
Henlius and Accord's Zercepac (trastuzumab- biosimilar) Receive the EMA Approval for HER2-Positive Breast Cancer and Gastric Cancer

Henlius and Accord's Zercepac (trastuzumab- biosimilar) Receive the EMA Approval for HER2-Positive Breast Cancer and Gastric Cance...

  • July 30, 2020
Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin) Receives the US FDA's Approval for Early and Metastatic HER2-Positive Breast Cancer

Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin) Receives the US FDA's Approval for Early and Metastatic HER2-Posi...

  • June 30, 2020
AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal Cancer and HER2-Mutant Non-Small Cell Lung Cancer #ASCO20

AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal...

  • June 1, 2020
Samsung Bioepis Reports Results of Ontruzant (biosimilar- trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locally Advanced HER2-Positive Breast Cancer

Samsung Bioepis Reports Results of Ontruzant (biosimilar- trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locall...

  • May 15, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.